Treatment Patterns of Oral Glucocorticoids in Patients with IgG4-Related Disease: A Real-World Analysis based on a Japanese Claims Database

Clicks: 16
ID: 339197
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #52 of 54 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Objectives To describe the prescribing patterns of oral glucocorticoid and evaluate flares and glucocorticoid-related complications in patients with immunoglobulin G4-related disease. Methods This retrospective observational study used a Japanese hospital claims database. Patients with a prescription for oral glucocorticoids, a diagnosis of immunoglobulin G4-related disease, and having at least two immunoglobulin G4 measurement tests were included. The index date was defined as the first oral glucocorticoid prescription recorded in the database (Day 0). Patients were followed for up to Day 1460 (4 years). Results The study included 3,167 patients. The mean dose of oral glucocorticoid was 28.76, 10.71, and 4.12 mg/day on Day 0, 90, and 1095, respectively. At Day 1460, 66.56% of the patients were still receiving oral glucocorticoid therapy and the dose exceeded 5 mg/day in 17.80% of patients. During the follow-up period, 453 patients (14.30%) experienced at least one flare. The incidence rates of hospitalized infections, osteoporotic fractures, and cardiovascular diseases, defined as serious glucocorticoid complications, were 7.46, 0.61, and 1.61 per 100 person-years, respectively. Conclusions Over half of the patients continued glucocorticoid therapy at 4 years. Glucocorticoid withdrawal strategies could be associated with reducing the long-term glucocorticoid-related toxicity in patients with immunoglobulin G4-related disease.
Reference Key
openalex_W7225458460 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag097
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.